Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1007/s11606-017-4279-4
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rivera Caravaca, José Miguel | - |
dc.contributor.author | Roldán Schilling, Vanessa | - |
dc.contributor.author | Romera, Marta | - |
dc.contributor.author | Esteve-Pastor, María Asunción | - |
dc.contributor.author | Valdés Chávarri, Mariano | - |
dc.contributor.author | Lip, Gregory YH | - |
dc.contributor.author | Vicente García, Vicente | - |
dc.contributor.author | Marín Ortuño, Francisco | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Enfermería | - |
dc.date.accessioned | 2024-02-07T09:42:32Z | - |
dc.date.available | 2024-02-07T09:42:32Z | - |
dc.date.issued | 2018-03-22 | - |
dc.identifier.citation | Journal of General Internal Medicine, 2018; 33(6):847–54 | es |
dc.identifier.uri | http://hdl.handle.net/10201/138864 | - |
dc.description | © Society of General Internal Medicine 2018. This document is the Published version of a Published Work that appeared in final form in Journal of General Internal Medicine. To access the final edited and published work see https://doi.org/10.1007/s11606-017-4279-4 | - |
dc.description.abstract | BACKGROUND: Soluble fibrin monomer complex (SFMC) is a biomarker of fibrin formation abnormally elevated in clinical situations of hypercoagulability. OBJECTIVE: We investigated the association and predictive performance of SFMC for stroke, adverse cardiovascular events, cardiovascular mortality and all-cause mortality in a cohort of patients with atrial fibrillation (AF) receiving vitamin K antagonist (VKA) anticoagulant therapy. DESIGN: During the second semester of 2007, we included 1226 AF outpatients stable on VKAs (INR 2.0–3.0) over a period of 6 months. SFMC levels were assessed at baseline. During 6.5 (IQR 4.4–8.0) years of follow-up, we recorded all ischemic strokes, adverse cardiovascular events (composite of stroke, acute heart failure, acute coronary syndrome and cardiovascular death), cardiovascular deaths and all-cause deaths. PARTICIPANTS: All patients were recruited consecutively. We excluded patients with rheumatic mitral valves, prosthetic heart valves, acute coronary syndrome, stroke, hemodynamic instability, hospital admissions or surgical interventions within the preceding 6 months. MAIN MEASURES: SFMClevelsweremeasured in plasma by immunoturbidimetry in an automated coagulometer (STALiatestFM, Diagnostica Stago, Asnieres, France). KEY RESULTS: We recorded 121 (1.52%/year) ischemic strokes, 257 (3.23%/year) cardiovascular events, 67 (0.84%/year) cardiovascular deaths and 486 (6.10%/year) all-cause deaths. SFMC >12 μg/mL was not associated with stroke but was associated with higher risk of cardiovascular events (HR 1.72, 95% CI 1.31–2.26), cardiovascular mortality (HR 2.16, 95% CI 1.30–3.57) and all-cause mortality (HR 1.26, 95% CI 1.03–1.55). When SFMC >12 μg/mL was added to the CHA2DS2-VASc, there were significant improvements in predictive performance, sensitivity and reclassification for adverse cardiovascular events (c-index: 0.645 vs. 0.660, p = 0.010; IDI = 0.013, p<0.001; NRI=0.121, p<0.001) and cardiovascular mortality (c-index: 0.661 vs. 0.691, p = 0.006; IDI = 0.009, p = 0.049; NRI = 0.217, p < 0.001), but decision curves demonstrated a similar net benefit and clinical usefulness. CONCLUSIONS: In AF patients taking VKAs, high SFMC levels were associated with the risk of adverse cardiovascular events, cardiovascular mortality and all-cause mortality. The addition of SFMC to the CHA2DS2-VASc score improved its predictive performance for these outcomes, but failed to show an improvement in clinical usefulness. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 | es |
dc.language | eng | es |
dc.publisher | Springer | - |
dc.relation | Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER) (PI13/00513 y P14/00253), Fundación Séneca (19245/PI/14) e Instituto Murciano de Investigación Biosanitaria (IMIB16/AP/01/06). | es |
dc.rights | info:eu-repo/semantics/embargoedAccess | es |
dc.subject | Fibrilación auricular | es |
dc.subject | Anticoagulantes | es |
dc.subject | Monómeros de fibrina | es |
dc.subject | Biomarcadores | es |
dc.subject | Trombosis | es |
dc.subject | Mortalidad | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina | es |
dc.title | Soluble fibrin monomer complex and prediction of cardiovascular events in atrial fibrillation: the observational Murcia atrial fibrillation project | es |
dc.type | info:eu-repo/semantics/article | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s11606-017-4279-4 | - |
dc.embargo.terms | Si | - |
dc.identifier.doi | https://doi.org/10.1007/s11606-017-4279-4 | - |
Aparece en las colecciones: | Artículos: Enfermería |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Soluble Fibrin Monomer Complex.pdf | 1,14 MB | Adobe PDF | Visualizar/Abrir Solicitar una copia |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.